The Initial Experience of Intraprostatic Injection of Botulinum Toxin Type A for Benign Prostatic Hyperplasia: A Comparative Study of Short-term Effect with Transurethral Resection of Prostate / 대한비뇨기과학회지

ABSTRACT

PURPOSE: To retrospectively compare the results of botulinum toxin type A (BTA) with those of transurethral resection of the prostate (TURP) in the treatment of benign prostatic hypertrophy (BPH) and to evaluate the effect of BTA. MATERIALS AND METHODS: The changes of symptom after BTA injection into prostate (BIP) and TURP in 26 patients treated with BIP and 81 patients treated with TURP were analysed retrospectively. All BPH-related medications were stopped immediately after BTA administration. To evaluate the effect of BIP, the parameters such as International Prostate Symptom Score (IPSS), quality of life (QoL), prostate-specific antigen (PSA), prostate volume, post-void residual urine and maximum flow rate were measured both before and 1 month after BIP. RESULTS: In both groups, IPSS and QoL were improved significantly after treatment, but the effectiveness of TURP was much superior to that of BIP. Among the patients with a prostate volume under 40ml, IPSS was improved by 27.5% in the BTA group and 38% in the TURP group. QoL was improved by 31.8% in the BTA group and 51% in the TURP group, but the difference between the two groups was not statistically significant. Among the patients with a prostate volume over 40ml, IPSS was improved by 24.7% in the BTA group and 47.6% in the TURP group. QoL was improved by 18.9% in the BTA group and 44.4% in the TURP group, and the difference was statistically significant between the two groups. CONCLUSIONS: Although both BIP and TURP significantly improved the clinical outcome, the latter was far superior to the former in improving voiding symptoms caused by BPH. However, BIP can be a new therapeutic option for patients with a small prostate volume or who want more minimally invasive treatment.